Revision Bulletin 29 Dec Jan 2018 Non-Botanical Dietary Supplements Compliance

Similar documents
Revision Bulletin 27 Jan Feb 2017 Non-Botanical Dietary Supplements Compliance

The Nitrofurantoin Capsules Revision Bulletin supersedes the currently official monograph.

Additionally, minor editorial changes have been made to update the monograph to current USP style.

Should you have any questions, please contact Mary P. Koleck, Ph.D., Scientific Liaison ( or

Dissolution Test 5 was validated using a Zodiac C18 brand of L1 column. The typical retention time for atorvastatin is about min.

Revision Bulletin Official April 1, 2014 Alprazolam 1

contents of the currently official monograph. Please refer to the current edition of the USP NF for official text.

Dissolution Test 2 was validated using an Inertsil ODS-3V brand of L1 column. The typical retention time for donepezil is about 5.5 min.

The Isosorbide Mononitrate Extended-Release Tablets Revision Bulletin supersedes the currently official monograph.

USP 36 Official Monographs / Metformin carding the first 3 ml of filtrate. Transfer 25 ml of the Analysis

contents of the currently official monograph. Please refer to the current edition of the USP NF for official text.

BRIEFING. (EXC: K. Moore.) RTS C Propylparaben C 10 H 12 O Benzoic acid, 4 hydroxy, propyl ester; Propyl p hydroxybenzoate [ ].

ANALYTICAL METHOD PROCEDURES

DETERMINATION OF DRUG RELEASE DURING DISSOLUTION OF NICORANDIL IN TABLET DOSAGE FORM BY USING REVERSE PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY

USP 35 Official Monographs / Oxaliplatin 4143 DEFINITION

TEMPLATE FOR AN EXAMPLE STANDARD TEST METHOD

ARTEMETHER AND LUMEFANTRINE TABLETS: Final text for addition to The International Pharmacopoeia (July 2008)

Chapter 4: Verification of compendial methods

LUMEFANTRINUM LUMEFANTRINE

NEVIRAPINE ORAL SUSPENSION Final text for addition to The International Pharmacopoeia (February 2009)

7. Stability indicating analytical method development and validation of Ramipril and Amlodipine in capsule dosage form by HPLC.

ARTEMETHER AND LUMEFANTRINE ORAL SUSPENSION:Final text for addition to The International Pharmacopoeia (November 2008)

Lonicera japonica Flower Dry Extract. Proposed For Development Version 0.1. Published on Herbal Medicines Compendium (

CYCLOSERINE Final text for addition to The International Pharmacopoeia. (November 2008) CYCLOSERINUM CYCLOSERINE

Lonicera japonica Flower Powder. Proposed For Development Version 0.1. Published on Herbal Medicines Compendium (

Change to read: PROCEDURE Buffer: 3.9 g/l of ammonium acetate in water. Adjust

Ondansetron Hydrochloride Tablets

USP Method Transfer and Routine Use Analysis of Irbesartan Tablets from HPLC to UPLC

IDENTIFICATION OF STEROIDS IN COSMETIC PRODUCTS BY TLC AND HPLC 1 02/12/2005 ACM 007 A. THIN LAYER CHROMATOGRAPHY (TLC)

USP 35 Official Monographs / Azithromycin 2279 C 38H 72N 2O 12 H 2O

EFAVIRENZ Final text for addition to The International Pharmacopoeia

DOXYCYCLINE HYCLATE Final text to replace published monograph in The International Pharmacopoeia (November 2007)

ADVANTAME. Not less than 97.0% and not more than 102.0% on the anhydrous basis. Sweetener, flavour enhancer

Egualen Sodium Granules

CHAPTER V ANALYTICAL METHODS ESTIMATION OF DICLOFENAC. Diclofenac (gift sample from M/s Micro Labs Ltd., Pondicherry)

Int. J. Pharm. Sci. Rev. Res., 30(2), January February 2015; Article No. 09, Pages: 63-68

Method Development and Validation Of Prasugrel Tablets By RP- HPLC

Journal of Drug Delivery and Therapeutics

MEDROXYPROGESTERONE INJECTION

Impact factor: 3.958/ICV: 4.10 ISSN:

Asian Journal of Research in Chemistry and Pharmaceutical Sciences Journal home page:

Volume 6, Issue 2, January February 2011; Article-015

LABORATORY EXERCISE: USING SPECTROPHOTOMETRY FOR QUALITY CONTROL: NIACIN

Fast methods for the determination of ibuprofen in drug products

BRIEFING. Pharmacopeial Discussion Group Sign Off Document Attributes EP JP USP Definition Loss on drying Readily carbonizable substances

CHAPTER INTRODUCTION OF DOSAGE FORM AND LITERATURE REVIEW

CHAPTER 19 PARACETAMOL + IBUPROFEN

Development and Validation of Stability Indicating RP-HPLC Method for the Determination of Anagrelide HCl in Pharmaceutical Formulation

A Simple, Novel Validated Stability Indicating RP-HPLC method for estimation of Duloxetine HCl in Capsule Pharmaceutical Formulation

Radhakrishnan K. et al. / International Journal of Pharmacy & Therapeutics, 3(1), 2012, e- ISSN Print ISSN

IDENTIFICATION AND DETERMINATION OF HYDROQUINONE IN COSMETIC PRODUCTS 2 14/11/17 ACM 003 BY TLC AND HPLC

Stability indicating RP-HPLC method for determination of azilsartan medoxomil in bulk and its dosage form

ADVANTAME (TENTATIVE)

Intercontinental journal of pharmaceutical Investigations and Research

CHAPTER - 3 ANALYTICAL PROFILE. 3.1 Estimation of Drug in Pharmaceutical Formulation Estimation of Drugs

This method describes the identification of the following prohibited colorants in cosmetic products:

Research Article METHOD DEVELOPMENT AND VALIDATION FOR SIMULTANEOUS ESTIMATION OF ELBASVIR AND GRAZOPREVIR BY RP-HPLC

METHOD DEVELOPMENT AND VALIDATION OF RALTEGRAVIR POTASSIUM AND RILPIVIRINE HCL BY HPLC AND HPTLC METHODS

DEVELOPMENT AND VALIDATION OF HPLC METHOD OF DISSOLUTION TEST FOR METOPROLOL SUCCINATE AND CILNIDIPINE

DEVELOPMENT AND VALIDATION OF RP-HPLC METHOD TO DETERMINE CINITAPRIDE HYDROGEN TARTARATE IN BULK AND PHARMACEUTICAL FORMULATION

A RP-HPLC METHOD DEVELOPMENT AND VALIDATION OF PARA- PHENYLENEDIAMINE IN PURE FORM AND IN MARKETED PRODUCTS

Journal of Pharmaceutical and Biomedical Analysis Letters. Analysis Letters

High Performance Liquid Chromatography. Table 1: Allowed HPLC Adjustment of USP <621> and EP <2.2.46>

Analytical Method Development and Validation of Lafutidine in Tablet dosage form by RP-HPLC

Chapter-4 EXPERIMENTAL WORK BY RP-HPLC

Pelagia Research Library

Dissolution study and method validation of alprazolam by high performance liquid chromatography method in pharmaceutical dosage form

Validated RP-HPLC Method for Estimation of Cefprozil in Tablet Dosage Form

Simultaneous HPLC Determination of Methocarbamol, Paracetamol and Diclofenac Sodium

DEVELOPMENT AND VALIDATION OF A HPLC METHOD FOR IN-VIVO STUDY OF DICLOFENAC POTASSIUM

King Saud University College of Pharmacy Department of Pharmaceutics. Biopharmaceutics PHT 414. Laboratory Assignments 2010 G 1431 H

á233ñ ELEMENTAL IMPURITIES PROCEDURES

CIPAC. CIPAC Free relevant impurities methods:

PHARMA SCIENCE MONITOR AN INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES

Practical Pharmaceutical Technology I USP Dissolution Method for PARACETAMOL 500 mg Tablets Section No. 6 Group D

What actually are dietary supplements? They are consumed in large quantities, but they

VALIDATION OF A UPLC METHOD FOR A BENZOCAINE, BUTAMBEN, AND TETRACAINE HYDROCHLORIDE TOPICAL SOLUTION

Appendix II- Bioanalytical Method Development and Validation

Development and Validation of Stability-Indicating RP-HPLC Method for Estimation of Atovaquone

Stability-indicating HPLC determination of tolterodine tartrate in pharmaceutical dosage form

Scholars Research Library. Rapid and sensitive RP-HPLC analytical method development and validation of Pioglitazone hydrochloride

Journal of Chemical and Pharmaceutical Research, 2017, 9(1): Research Article

Analytical method development and validation of gabapentin in bulk and tablet dosage form by using UV spectroscopic method

Chapter 5: Identification, Assay and Related Substances

RP-HPLC Method Development and Validation of Dapagliflozin in Bulk and Tablet formulation

Mashhour Ghanem 1 and Saleh Abu-Lafi 2 * ABSTRACT ARTICLE INFO

International Journal of Pharma and Bio Sciences

Determination of Caffeine by HPLC

School of Chemistry UNIVERSITY OF KWAZULU-NATAL, WESTVILLE CAMPUS JUNE 2009 EXAMINATION CHEM340: INSTRUMENTAL ANALYSIS.

Draft Method proposal: determination of glucoheptonic acid (HGA) in fertilizers.

TECHNICAL BRODIFACOUM

J Pharm Sci Bioscientific Res (4): ISSN NO

High-Performance Liquid Chromatographic Method for the Analysis of Fluconazole in Pharmaceutical Preparations

Spectroscopic Method For Estimation of Atorvastatin Calcium in Tablet Dosage Form

Determination of Carbonyl Compounds In Water by Dinitrophenylhydrazine Derivatization and HPLC/UV*

PYRIPROXYFEN TECHNICAL

Diquat 1,1 -ethylene-2,2 -bipyridium dibromide salt Paraquat 1,1 -dimethyl-4,4 -bipyridium dichloride salt Initial Preparation

Development and Validation of a HPLC Method for Determination of Anastrozole in Tablet Dosage Form

FLUDEOXYGLUCOSE ( 18 F) INJECTION: Final text for addition to The International Pharmacopoeia (January 2009)

Dehydrated Alcohol. » Dehydrated Alcohol contains not less than 99.2 percent, Pharmacopeial Forum Vol. 30(5) [Sept. Oct. 2004] HARMONIZATION 1847

Transcription:

Niacin Extended-Release Tablets Type of Posting Posting Date Official Date Expert Committee Reason for Revision Revision Bulletin 29 Dec 2017 01 Jan 2018 Non-Botanical Dietary Supplements Compliance In accordance with the Rules and Procedures of the 2015-2020 Council of Experts, the Non-Botanical Dietary Supplement Expert Committee has revised the Niacin Extended-Release Tablets monograph. The purpose for the revision is to add Dissolution Test 5 for drug product approved by the FDA. The Niacin Extended-Release Tablets Revision Bulletin supersedes the currently official monograph. The Revision Bulletin will be incorporated in the Second Supplement to USP 41 NF 36. Should you have any questions, please contact Natalia Davydova (301 816-8328 or nd@usp.org)

. Solution Revision Bulletin Official January 1, 2018 Niacin 1 Niacin Extended-Release Tablets DEFINITION Niacin Extended-Release Tablets contain NLT 90.0% and NMT 110.0% of the labeled amount of niacin (C 6H 5NO 2). IDENTIFICATION A. The retention time of the major peak of the Sample solution corresponds to that of the Standard solution, as obtained in the Assay. A: Solution of sodium heptanesulfonate in acetic acid, methanol, and water (4:44:33:19), w/w 1. Mobile phase: Mixture of methanol, water, and Solution A (560:440:25) Standard solution: USP Niacin RS at a known concentration in water in the range of 75 750 µg/ml Sample solution: Filtered portion of the solution under test suitably diluted with Medium if necessary Chromatographic system (See Chromatography 621, System Suitability.) Mode: LC Detector: UV 254 nm Column: 3.9-mm 15-cm; 10-µm packing L1 Flow rate: 1.0 ml/min Injection volume: 15 µl System suitability Sample: Standard solution Tailing factor: NMT 2.0 Relative standard deviation: NMT 2.0% Determine, in mg/ml, the content of niacin (C 6H 5NO 2) in the Medium at each time point: ASSAY PROCEDURE Diluent: Methanol and water (82:18) Mobile phase: Methanol and water (82:18), adjusted with glacial acetic acid to a ph of 3.15 ± 0.05 Standard solution: 250 µg/ml of USP Niacin RS, 50 µg/ml of USP 6-Hydroxynicotinic Acid RS, and 97.8 µg/ml of pyridine in Diluent Sample solution: Transfer a quantity of powder, equivalent to 50 mg of niacin from NLT 20 finely powdered Tablets, to a suitable flask, add Diluent, and stir for 2 h. Dilute with Diluent to a final concentration of 250 µg/ ml of niacin. Result = (r U/r S) C S D Chromatographic system (See Chromatography 621, System Suitability.) r U = peak area of niacin from the Sample solution Mode: LC r S = peak area of niacin from the Standard solution Detector: UV 260 nm Column: 4.6-mm 15-cm; 5-µm packing L8 Flow rate: 1.0 ml/min D = dilution factor for the Sample solution Injection volume: 25 µl System suitability Sample: Standard solution [NOTE See Table 4 for relative retention times.] Resolution: NLT 1.5 between pyridine and 6-hydrox- At 3 h: ynicotinic acid, and NLT 1.5 between 6-hydroxynicotinic acid and niacin Result 2 = [C 2 (V V S) + C 1 V S] 100/L Relative standard deviation: NMT 3.0% for each of the peaks Result 3 = [C 3 (V 2 V S) + (C 1 + C 2) V S] 100/L niacin (C 6H 5NO 2) in the portion of Tablets taken: At 9 h: Result = (r U/r S) (C S/C U) 100 Result 4 = [C 4 (V 3 V S) + (C 1 + C 2 + C 3) V S] 100/L r U = peak area of niacin from the Sample solution r S = peak area of niacin from the Standard solution At 12 h: Result 5 = [C 5 (V 4 V S) + (C 1 + C 2 + C 3 + C 4) V S] C U = nominal concentration of niacin in the Sample 100/L solution (mg/ml) Acceptance criteria: 90.0% 110.0% At 20 h: PERFORMANCE TESTS Result 6 = [C 6 (V 5 V S) + (C 1 + C 2 + C 3 + C 4 + C 5) V S] 100/L Change to read: C = as C 1, C 2,, C 6, the content of niacin in the Medium at each time point (mg/ml) DISSOLUTION 711 V = volume of Medium, 900 ml Test 1 V S = volume of sample withdrawn at each time Apparatus 1: 100 rpm L = label claim (mg/tablet) s: 1, 3, 6, 9, 12, and 20 h; without Medium re- Tolerances: The percentage of the labeled amount of placement. [NOTE Withdraw the same volume at each time point.] Table 1, Table 2, and Table 3 conforms to Dissolution 711, Acceptance Table 2. 1. Commercially available from Waters Corporation as PIC B7 Reagent (Part #85103).

2 Niacin Official January 1, 2018 Table 1. For Tablets Labeled to Contain 500 mg or For Tablets labeled to contain 1000 mg: Dilute a Less/Tablet filtered portion of the solution under test with appropriate dissolution medium 50-fold. Instrumental conditions (See Ultraviolet-Visible Spectroscopy 857.) Mode: UV 3 17 32 Analytical wavelength: 262 nm 6 33 48 Path length: 1 cm 9 43 63 Blank: Acid stage medium or Buffer stage medium 12 52 77 Samples: Standard solution 1 or Standard solution 2 20 NLT 75 and Sample solution Determine the concentration, in mg/ml, of niacin (C 6H 5NO 2) in the sample withdrawn from the vessel Table 2. For Tablets Labeled to Contain 750 mg/tablet at each time point: Result = [(A U A B)/A S] C S D A U = absorbance of the Sample solution 3 16 31 A B = absorbance of the Blank 6 31 46 A S = absorbance of the Standard solution 9 42 62 12 51 76 20 NLT 75 D = dilution factor for the Sample solution Table 3. For Tablets Labeled to Contain 1000 mg/tablet Result 1 = (C 1 V) 100/L At 4 h: 3 15 30 Result 2 = (C 2 V + C 1 V S) 100/L 6 30 45 9 40 60 At 12 h: Result 3 = [(C 3 + C 2) V + C 1 V S] 100/L Test 2: If the product complies with this test, the labeling indicates that it meets USP Dissolution Test 2. Result 4 = [(C 4 + C 2) V + (C 1 + C 3) V S] 100/L Acid stage medium: 0.1 N hydrochloric acid; 900 ml Buffer stage medium: 6.8 g of monobasic potassium C = as C 1,, C 4, the content of niacin in the phosphate and 0.89 g of sodium hydroxide pellets in related dissolution medium at each time 1000 ml of water. Adjust with diluted sodium hydrox- point (mg/ml) ide or phosphoric acid to a ph of 6.8; 900 ml. V = volume of Medium, 900 ml Apparatus 1: 100 rpm V S = volume of sample withdrawn at each time s: 1, 4, 12, and 24 h: 1 and 4 h in the Acid stage medium; 12 and 24 h in the Buffer stage medium. Re- L = label claim (mg/tablet) place the volume withdrawn with the equal volume Tolerances: The percentage of the labeled amount of of medium preheated to 37 ± 0.5. Procedure: After 4 h replace the Acid stage medium Table 4 and Table 5 conforms to Dissolution 711, Acwith the Buffer stage medium, and run the test for the ceptance Table 2. times specified (additional 20 h for a total of 24 h). Pass a portion of the solution through a suitable Table 4. For Tablets Labeled to Contain 500 mg/tablet filter.] Standard stock solution: 0.2 mg/ml of USP Niacin RS in water 1 NMT 25 Standard solution 1: Dilute Standard stock solution 4 30 50 with Acid stage medium to a final concentration of 0.01 mg/ml of USP Niacin RS. 12 65 85 Standard solution 2: Dilute Standard stock solution with Buffer stage medium to a final concentration of 0.01 mg/ml of USP Niacin RS. Sample solution Table 5. For Tablets Labeled to Contain 750 and 1000 mg/ For Tablets labeled to contain 500 mg: Dilute a Tablet filtered portion of the solution under test with ap- propriate dissolution medium 25-fold. For Tablets labeled to contain 750 mg: Dilute a filtered portion of the solution under test with ap- 1 NMT 25 propriate dissolution medium 33-fold. 4 30 50 12 50 75 20 NLT 75

Official January 1, 2018 Niacin 3 Table 5. For Tablets Labeled to Contain 750 and 1000 mg/ At 12 h: Tablet (Continued) Result 5 = [C 5 (V 4 V S) + (C 1 + C 2 + C 3 + C 4) V S] 100/L 12 55 75 At 20 h: Result 6 = [C 6 (V 5 V S) + (C 1 + C 2 + C 3 + C 4 + C 5) Test 3: If the product complies with this test, the label- V S] 100/L ing indicates that it meets USP Dissolution Test 3. C = as C 1, C 2,, C 6, the content of niacin in the Apparatus 1: 100 rpm Medium at each time point (mg/ml) s: 1, 3, 6, 9, 12, and 20 h; without Medium V = volume of Medium, 900 ml replacement V S = volume of sample withdrawn at each time Pass a portion of the solution through a stainless steel L = label claim (mg/tablet) filter.] Tolerances: The percentage of the labeled amount of Solution A: 1 mg/ml of sodium 1-hexanesulfonate Table 6 and Table 7 conforms to Dissolution 711, Ac- ceptance Table 2. monohydrate in water Mobile phase: Mixture of Solution A, methanol, and glacial acetic acid (840:150:10) Standard solution: (L/900) mg/ml of USP Niacin RS Table 6. For Tablets Labeled to Contain 500 and 1000 mg/ Tablet in Medium, where L is the label claim in mg/tablet [NOTE Use sonication for complete dissolution, if necessary.] Sample solution: Filtered portion of the solution under test 1 NMT 20 Chromatographic system 3 15 35 (See Chromatography 621, System Suitability.) 6 30 50 Mode: LC 9 40 65 Sample cooler: 10 12 50 80 Detector: UV 262 nm Column: 3.9-mm 15-cm; 10-µm packing L1 Column temperature: 40 Flow rate: 1.5 ml/min 20 NLT 70 Injection volume: 2 µl Table 7. For Tablets Labeled to Contain 750 mg/tablet System suitability Sample: Standard solution 1 NMT 16 Theoretical plates: NLT 1000 Tailing factor: NMT 2.0 3 15 35 Relative standard deviation: NMT 2.0% 6 30 50 9 40 65 12 50 75 Determine the concentration, in mg/ml, of niacin 20 NLT 75 (C 6H 5NO 2) in the Medium at each time point: Result = (r U/r S) C S Test 4: If the product complies with this test, the labeling indicates that it meets USP Dissolution Test 4. r U = peak area of niacin from the Sample solution Apparatus 1: 100 rpm r S = peak area of niacin from the Standard solution s: 1, 3, 6, 9, 12, and 24 h for Tablets labeled to contain 500 and 1000 mg/tablet, and 1, 6, 12, and 24 h for Tablets labeled to contain 750 mg/tablet; without Medium replacement Pass a portion of the solution through a 0.45-µm PVDF membrane filter, discarding the first 2 ml of the filtrate.] At 3 h: Standard stock solution: 0.5 mg/ml of USP Niacin RS in water Result 2 = [C 2 (V V S) + C 1 V S] 100/L Standard solution: Dilute Standard stock solution with Medium to a final concentration of 0.02 mg/ml of USP Niacin RS. Sample solution Result 3 = [C 3 (V 2 V S) + (C 1 + C 2) V S] 100/L For Tablets labeled to contain 500 mg: Dilute a filtered portion of the solution under test with Me- At 9 h: dium 25-fold. For Tablets labeled to contain 750 mg: Dilute a Result 4 = [C 4 (V 3 V S) + (C 1 + C 2 + C 3) V S] filtered portion of the solution under test with Me- 100/L dium 40-fold.

4 Niacin Official January 1, 2018 For Tablets labeled to contain 1000 mg: Dilute a C = as C 1, C 2,, C 6, the content of niacin in the filtered portion of the solution under test with Me- Medium at each time point (mg/ml) dium 50-fold. V = volume of Medium, 900 ml Instrumental conditions V S = volume of sample withdrawn at each time (See Ultraviolet-Visible Spectroscopy 857.) Mode: UV L = label claim (mg/tablet) Analytical wavelength: 262 nm Tolerances: The percentage of the labeled amount of Path length: 1 cm Blank: Medium Table 8, Table 9, and Table 10 conforms to Dissolution 711, Acceptance Table 2. Determine the concentration, in mg/ml, of niacin Table 8. For Tablets Labeled to Contain 500 mg/tablet (C 6H 5NO 2) in the sample withdrawn from the vessel at each time point: Result = [(A U A B)/A S] C S D 3 17 32 A U = absorbance of the Sample solution 6 33 48 A B = absorbance of the Blank A 9 48 68 S = absorbance of the Standard solution 12 60 80 D = dilution factor for the Sample solution For Tablets labeled to contain 500 and 1000 mg: Table 9. For Tablets Labeled to Contain 750 mg/tablet 6 20 40 At 3 h: 12 48 68 Result 2 = [C 2 (V V S) + C 1 V S] 100/L Table 10. For Tablets Labeled to Contain 1000 mg/tablet Result 3 = [C 3 (V 2 V S) + (C 1 + C 2) V S] 100/L At 9 h: Result 4 = [C 4 (V 3 V S) + (C 1 + C 2 + C 3) V S] 3 12 27 100/L 6 25 45 9 35 55 At 12 h: 12 50 70 Result 5 = [C 5 (V 4 V S) + (C 1 + C 2 + C 3 + C 4) V S] 100/L.Test 5: If the product complies with this test, the labeling indicates that it meets USP Dissolution Test 5. Result 6 = [C 6 (V 5 V S) + (C 1 + C 2 + C 3 + C 4 + C 5) Apparatus 1: 100 rpm V S] 100/L s: 1, 6, 12, and 24 h; without Medium replacement For Tablets labeled to contain 750 mg: Calculate the percentage of the labeled amount of niacin Pass a portion of the solution through a 0.45-µm ny- (C 6H 5NO 2) dissolved at each time point: lon membrane filter, discarding the first 2 ml of the filtrate.] Solution A: 1.1 mg/ml of sodium 1-heptanesulfonate in water Mobile phase: Mixture of Solution A and methanol (70:30) Result 2 = [C 2 (V V S) + C 1 V S] 100/L Standard solution: 0.84 mg/ml of USP Niacin RS in water At 12 h: [NOTE Use sonication for complete dissolution, if necessary.] Result 3 = [C 3 (V 2 V S) + (C 1 + C 2) V S] 100/L Sample solution: Filtered portion of the solution under test Chromatographic system (See Chromatography 621, System Suitability.) Result 4 = [C 4 (V 3 V S) + (C 1 + C 2 + C 3) V S] 100/L

Official January 1, 2018 Niacin 5 Mode: LC Detector: UV 262 nm Column: 4.6-mm 25-cm; 5-µm packing L1 Column temperature: 30 Flow rate: 1.0 ml/min Injection volume: 5 µl System suitability Sample: Standard solution Tailing factor: NMT 2.0 Relative standard deviation: NMT 2.0% Determine the concentration, in mg/ml, of niacin (C 6H 5NO 2) in the Medium at each time point: r U r S C S Result = (r U/r S) C S = peak area of niacin from the Sample solution = peak area of niacin from the Standard solution = concentration of USP Niacin RS in the (RB 1-Jan-2018) UNIFORMITY OF DOSAGE UNITS 905 : Meet the requirements IMPURITIES ORGANIC IMPURITIES Diluent, Mobile phase, Standard solution, Sample solution, Chromatographic system, and System suitability: Proceed as directed in the Assay. Calculate the percentage of 6-hydroxynicotinic acid or pyridine in the portion of Tablets taken: Result = (r U/r S) (C S/C U) 100 r U = peak area of 6-hydroxynicotinic acid or pyridine from the Sample solution r S = peak area of 6-hydroxynicotinic acid or pyridine from the Standard solution C S = concentration of USP 6-Hydroxynicotinic Acid RS or pyridine in the Standard solution (µg/ml) C U = nominal concentration of niacin in the Sample solution (µg/ml) Calculate the percentage of any unspecified impurity in the portion of Tablets taken: Result = (r U/r S) (C S/C U) 100 Result 2 = [C 2 (V V S) + C 1 V S] 100/L r U = peak area of each impurity from the Sample solution At 12 h: r S = peak area of niacin from the Standard solution Result 3 = [C 3 (V 2 V S) + (C 1 + C 2) V S] 100/L Standard solution (µg/ml) C U = nominal concentration of niacin in the Sample solution (µg/ml) Result 4 = [C 4 (V 3 V S) + (C 1 + C 2 + C 3) V S] Acceptance criteria: See Table 13. 100/L Table 13 C = as C 1,, C 4, the content of niacin in the Relative Acceptance Medium at each time point (mg/ml) Retention Criteria, V = volume of Medium, 900 ml Name NMT (%) L = label claim (mg/tablet) Pyridine 0.14 0.2 V S = volume of sample withdrawn at each time 6-Hydroxynicotinic acid 0.64 0.2 Tolerances: The percentage of the labeled amount of Niacin 1.0 Any unspecified impurity 0.1 Table 11 and Table 12 conforms to Dissolution 711, Acceptance Table 2. Total impurities 1.0 ADDITIONAL REQUIREMENTS Table 11. For Tablets Labeled to Contain 500 mg/tablet PACKAGING AND STORAGE: Preserve in tight containers. LABELING: When more than one Dissolution test is given, the labeling states the Dissolution test used only if Test 1 1 NMT 20 is not used. USP REFERENCE STANDARDS 11 6 30 50 USP 6-Hydroxynicotinic Acid RS 12 50 75 USP Niacin RS Table 12. For Tablets Labeled to Contain 1000 mg/tablet 1 NMT 20 6 20 40 12 45 65